Literature DB >> 19476424

An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse.

Annie Wong-Beringer1, Lee H Nguyen, Michelle Lee, Kimberly A Shriner, Jean Pallares.   

Abstract

The fluoroquinolones have become the leading class of antimicrobial agents prescribed to adults in the United States. Resistance of key pathogens to fluoroquinolones has developed rapidly in parallel with increased prescribing of these drugs. We describe our pharmacist-led antimicrobial stewardship program that focused on reducing inappropriate prescribing of fluoroquinolones, with the goals of limiting the development of resistance and improving patient outcomes. Core strategies were regular monitoring and reporting of resistance trends observed on institutional antibiograms, performing drug audits and related studies with intervention and feedback to prescribers, implementing an automatic parenteral-to-oral conversion program, establishing and implementing a beta-lactam-based institutional guideline for empiric therapy, and educating prescribers. This successful program reduced empiric prescribing of fluoroquinolones by 30%, improved susceptibility for all antipseudomonal agents against Pseudomonas aeruginosa overall by 10%, and decreased mortality associated with P. aeruginosa infections by 2-fold. Our stewardship program clearly demonstrated that pharmacists can take on leadership roles to positively change antimicrobial prescribing at the institutional level and improve patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19476424     DOI: 10.1592/phco.29.6.736

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  19 in total

1.  Prospective audit and feedback on antibiotic prescription in an adult hematology-oncology unit in Singapore.

Authors:  C-L Yeo; D S-G Chan; A Earnest; T-S Wu; S-F Yeoh; R Lim; R Jureen; D Fisher; L-Y Hsu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-08-04       Impact factor: 3.267

2.  Use of computer decision support in an antimicrobial stewardship program (ASP).

Authors:  R S Evans; J A Olson; E Stenehjem; W R Buckel; E A Thorell; S Howe; X Wu; P S Jones; J F Lloyd
Journal:  Appl Clin Inform       Date:  2015-03-03       Impact factor: 2.342

3.  Development of antimicrobial competencies and training for staff hospital pharmacists.

Authors:  Marsha F Crader
Journal:  Hosp Pharm       Date:  2014-01

4.  Effect of a Health Care System Respiratory Fluoroquinolone Restriction Program To Alter Utilization and Impact Rates of Clostridium difficile Infection.

Authors:  Katherine M Shea; Athena L V Hobbs; Theresa C Jaso; Jack D Bissett; Christopher M Cruz; Elizabeth T Douglass; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

5.  Targets for antibiotic and healthcare resource stewardship in inpatient community-acquired pneumonia: a comparison of management practices with National Guideline Recommendations.

Authors:  T C Jenkins; S A Stella; L Cervantes; B C Knepper; A L Sabel; C S Price; L Shockley; M E Hanley; P S Mehler; W J Burman
Journal:  Infection       Date:  2012-11-17       Impact factor: 3.553

6.  Urinary Tract Infections: Leading Initiatives in Selecting Empiric Outpatient Treatment (UTILISE).

Authors:  Eric Landry; Linda Sulz; Ali Bell; Lane Rathgeber; Heather Balogh
Journal:  Can J Hosp Pharm       Date:  2014-03

Review 7.  Safety Concerns Surrounding Quinolone Use in Children.

Authors:  Karisma Patel; Jennifer L Goldman
Journal:  J Clin Pharmacol       Date:  2016-03-28       Impact factor: 3.126

8.  Preferential Use of Nitrofurantoin Over Fluoroquinolones for Acute Uncomplicated Cystitis and Outpatient Escherichia coli Resistance in an Integrated Healthcare System.

Authors:  Rebecca L Pedela; Katherine C Shihadeh; Bryan C Knepper; Michelle K Haas; William J Burman; Timothy C Jenkins
Journal:  Infect Control Hosp Epidemiol       Date:  2017-01-05       Impact factor: 3.254

9.  Ambulatory Fluoroquinolone Use in the United States, 2015-2019.

Authors:  Siddhi Pramod Umarje; Caleb G Alexander; Andrew J Cohen
Journal:  Open Forum Infect Dis       Date:  2021-10-23       Impact factor: 3.835

10.  Fluoroquinolone Prescribing for Diabetic Foot Infections following an FDA Drug Safety Communication for Aortic Aneurysm Risk.

Authors:  Catherine Li; Nicholas J Mercuro; Ryan W Chapin; Howard S Gold; Christopher McCoy
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.